FDA Commissioner Marty Makary Resigns; Diamantas Named Acting Leader

1-Minute Brief

The leadership change at the FDA comes amid reported internal disputes and external political pressures affecting regulatory decisions.

Key Facts

• FDA Commissioner Marty Makary has resigned from his position.
• Makary's resignation follows reported clashes over the abortion drug mifepristone.
• Pro-life groups had expressed frustration with Makary's leadership, according to Fox News.
• Diamantas has been named the new acting FDA commissioner.
• Reports indicate President Trump approved a plan to remove Makary as FDA commissioner.

What Happened

Marty Makary has stepped down as FDA commissioner, and Diamantas has been appointed as the acting leader of the agency. The resignation follows reported internal and external pressures.

Why It Matters

Leadership changes at the FDA can influence regulatory policy and the agency's approach to contentious issues such as drug approvals and public health oversight.

What's Next

Observers will watch for policy shifts under Diamantas and any changes in the FDA's handling of high-profile regulatory matters.